Myomo completed its initial public offering (IPO) under SEC Regulation A+, raising $5.0 Million through the sale of 665k shares of its common stock at a price to the public of $7.50 per share. The company also raised $2.9 mill through investments by accredited investors in restricted securities, primarily from existing Myomo investors. The combined capital raised is $7.9 Million, adding to $20 million the company had raised beforehand.

Myomo is a medical robotics company that provides improved mobility for patients who suffer from upper limb paralysis and other neurological disorders. Their products have inherent consumer appeal which is very important at this early stage of the establishment of Reg A+ as a recognized capital raising and liquidity system. This consumer appeal provided the potential for online marketing to build interest and investment flow from consumers.

Because Myomo took a hybrid approach to it's Reg A+ IPO, successfully raising capital from both Wall Street (retail brokerage) and Main Street investors, they created a win-win situation where the combination made for a critical mass of investors and ultimately their IPO completion.

Myomo started their offering in early March and completed it in just less than three months.

Paul Gudonis, CEO of Myomo said: “While a traditional public offering is generally reserved for large institutions and the Wall Street elite to invest at this stage, we are taking advantage of new SEC regulations to level the playing field for all investors to participate concurrently in our IPO.”

TriPoint Global Equities, LLC, lead the broker-dealer syndicate and book runner for the offering. CrowdfundX drove digital marketing. All involved service providers.